<DOC>
	<DOCNO>NCT01178346</DOCNO>
	<brief_summary>The purpose study look pharmacoeconomic data subject receive either NicVAX placebo Nabi-4514 Nabi-4515 study .</brief_summary>
	<brief_title>Pharmacoeconomic Assessment Nabi-4514 Nabi-4515 Phase 3 Studies</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects eligible randomization reach Week 12 Nabi4514 Nabi4515 study . Subjects agree participate healthrelated quality life study . Subjects unable complete HRQoL questionnaire inability understand language due mental impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pharmacoeconomic</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Health Outcomes</keyword>
	<keyword>Smoking</keyword>
	<keyword>NicVAX</keyword>
	<keyword>Smoking vaccine</keyword>
	<keyword>Smoking cessation</keyword>
</DOC>